Biogen presents Phase 1b salanersen data showing 75% NfL reductions in children with SMA after gene therapy

Reuters03-11

Biogen presents Phase 1b salanersen data showing 75% NfL reductions in children with SMA after gene therapy

Biogen reported additional Phase 1b results for salanersen, a once-yearly antisense oligonucleotide for spinal muscular atrophy $(SMA)$, in children who previously received onasemnogene abeparvovec-xioi. The results were presented at the 2026 MDA Clinical & Scientific Conference and are also planned for presentation at the 5th International Scientific Congress on SMA (SMA Europe 2026). In the Phase 1b analysis (n=24; ages 0.5–12 years), participants with elevated baseline neurofilament light chain showed 75% reductions at six months that were sustained through follow-up. Biogen also outlined a Phase 3 program evaluating once-yearly salanersen 80 mg across three global studies: STELLAR-1, STELLAR-2, and SOLAR. STELLAR-1 has initiated screening, with SOLAR planned to initiate in Q2 2026 and STELLAR-2 in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110800OMX_____CNEWS_EN_GNW9669998_en) on March 11, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618944460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618944460","market":"us","top_or_hot":-1,"title":"Biogen presents Phase 1b salanersen data showing 75% NfL reductions in children with SMA after gene therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biogen presents Phase 1b salanersen data showing 75% NfL reductions in children with SMA after gene therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biogen reported additional Phase 1b results for salanersen, a once-yearly antisense oligonucleotide for spinal muscular atrophy <a href=\"https://laohu8.com/S/SMA\">$(SMA)$</a>, in children who previously received onasemnogene abeparvovec-xioi. The results were presented at the 2026 MDA Clinical &amp; Scientific Conference and are also planned for presentation at the 5th International Scientific Congress on SMA (SMA Europe 2026). In the Phase 1b analysis (n=24; ages 0.5–12 years), participants with elevated baseline neurofilament light chain showed 75% reductions at six months that were sustained through follow-up. Biogen also outlined a Phase 3 program evaluating once-yearly salanersen 80 mg across three global studies: STELLAR-1, STELLAR-2, and SOLAR. STELLAR-1 has initiated screening, with SOLAR planned to initiate in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026 and STELLAR-2 in Q3 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110800OMX_____CNEWS_EN_GNW9669998_en) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen presents Phase 1b salanersen data showing 75% NfL reductions in children with SMA after gene therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen presents Phase 1b salanersen data showing 75% NfL reductions in children with SMA after gene therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-11 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biogen presents Phase 1b salanersen data showing 75% NfL reductions in children with SMA after gene therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biogen reported additional Phase 1b results for salanersen, a once-yearly antisense oligonucleotide for spinal muscular atrophy <a href=\"https://laohu8.com/S/SMA\">$(SMA)$</a>, in children who previously received onasemnogene abeparvovec-xioi. The results were presented at the 2026 MDA Clinical &amp; Scientific Conference and are also planned for presentation at the 5th International Scientific Congress on SMA (SMA Europe 2026). In the Phase 1b analysis (n=24; ages 0.5–12 years), participants with elevated baseline neurofilament light chain showed 75% reductions at six months that were sustained through follow-up. Biogen also outlined a Phase 3 program evaluating once-yearly salanersen 80 mg across three global studies: STELLAR-1, STELLAR-2, and SOLAR. STELLAR-1 has initiated screening, with SOLAR planned to initiate in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026 and STELLAR-2 in Q3 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110800OMX_____CNEWS_EN_GNW9669998_en) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL6wsym0:1","article_id":"2618944460","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618944460","pubTimestamp":1773230429,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biogen reported additional Phase 1b results for salanersen, a once-yearly antisense oligonucleotide for spinal muscular atrophy , in children who previously received onasemnogene abeparvovec-xioi. The results were presented at the 2026 MDA Clinical & Scientific Conference and are also planned for presentation at the 5th International Scientific Congress on SMA . In the Phase 1b analysis , participants with elevated baseline neurofilament light chain showed 75% reductions at six months that were sustained through follow-up. Biogen also outlined a Phase 3 program evaluating once-yearly salanersen 80 mg across three global studies: STELLAR-1, STELLAR-2, and SOLAR. STELLAR-1 has initiated screening, with SOLAR planned to initiate in Q2 2026 and STELLAR-2 in Q3 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BIIB":"渤健公司","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4532":"文艺复兴科技持仓","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4588":"碎股","BK4112":"金融交易所和数据","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Biogen公布1b期salanersen数据显示基因治疗后SMA儿童NfL降低75%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"BIIB":0.9},"content_text":"Biogen presents Phase 1b salanersen data showing 75% NfL reductions in children with SMA after gene therapy\n    \n\n        Biogen reported additional Phase 1b results for salanersen, a once-yearly antisense oligonucleotide for spinal muscular atrophy $(SMA)$, in children who previously received onasemnogene abeparvovec-xioi. The results were presented at the 2026 MDA Clinical & Scientific Conference and are also planned for presentation at the 5th International Scientific Congress on SMA (SMA Europe 2026). In the Phase 1b analysis (n=24; ages 0.5–12 years), participants with elevated baseline neurofilament light chain showed 75% reductions at six months that were sustained through follow-up. Biogen also outlined a Phase 3 program evaluating once-yearly salanersen 80 mg across three global studies: STELLAR-1, STELLAR-2, and SOLAR. STELLAR-1 has initiated screening, with SOLAR planned to initiate in Q2 2026 and STELLAR-2 in Q3 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110800OMX_____CNEWS_EN_GNW9669998_en) on March 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618944460","isCrawlerRequest":true}